|
HY-RI01260A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4687-5p antagomir
|
|
|
|
|
HY-RI01260-20nmol
|
MedChemexpress LLC
|
hsa-miR-4687-5p inhibitor
|
|
|
|
|
HY-RI01260-5nmol
|
MedChemexpress LLC
|
hsa-miR-4687-5p inhibitor
|
|
|
|
|
HY-R01260-20nmol
|
MedChemexpress LLC
|
hsa-miR-4687-5p mimic
|
|
Cancer-programmed cell death
|
|
|
HY-R01260-5nmol
|
MedChemexpress LLC
|
hsa-miR-4687-5p mimic
|
|
Cancer-programmed cell death
|
|
|
HY-R01261A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4688 agomir
|
|
|
|
|
HY-R01261A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4688 agomir
|
|
|
|
|
HY-RI01261A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4688 antagomir
|
|
|
|
|
HY-RI01261A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4688 antagomir
|
|
|
|
|
HY-RI01261-20nmol
|
MedChemexpress LLC
|
hsa-miR-4688 inhibitor
|
|
|
|
|
HY-RI01261-5nmol
|
MedChemexpress LLC
|
hsa-miR-4688 inhibitor
|
|
|
|
|
HY-R01261-20nmol
|
MedChemexpress LLC
|
hsa-miR-4688 mimic
|
|
Cancer-programmed cell death
|
|
|
HY-R01261-5nmol
|
MedChemexpress LLC
|
hsa-miR-4688 mimic
|
|
Cancer-programmed cell death
|
|
|
HY-R01262A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4689 agomir
|
|
|
|
|
HY-R01262A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4689 agomir
|
|
|
|
|
HY-RI01262A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4689 antagomir
|
|
|
|
|
HY-RI01262A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4689 antagomir
|
|
|
|
|
HY-RI01262-20nmol
|
MedChemexpress LLC
|
hsa-miR-4689 inhibitor
|
|
|
|
|
HY-RI01262-5nmol
|
MedChemexpress LLC
|
hsa-miR-4689 inhibitor
|
|
|
|
|
HY-R01262-20nmol
|
MedChemexpress LLC
|
hsa-miR-4689 mimic
|
|
Cancer-programmed cell death
|
|
|
HY-R01262-5nmol
|
MedChemexpress LLC
|
hsa-miR-4689 mimic
|
|
Cancer-programmed cell death
|
|
|
HY-R01263A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4690-3p agomir
|
|
|
|
|
HY-R01263A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4690-3p agomir
|
|
|
|
|
HY-RI01263A-20nmol
|
MedChemexpress LLC
|
hsa-miR-4690-3p antagomir
|
|
|
|
|
HY-RI01263A-5nmol
|
MedChemexpress LLC
|
hsa-miR-4690-3p antagomir
|
|
|
|
